AstraZeneca PLC logo
AstraZeneca PLC AZN

Annual report 2025
added 03-14-2026

report update icon

AstraZeneca PLC General and Administrative Expenses 2011-2026 | AZN

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.
What these expenses include
  • Salaries of administrative staff (executives, HR, accountants, legal personnel)
  • Office rent and utilities
  • Office equipment and IT infrastructure
  • Professional services (auditors, lawyers, consultants)
  • Insurance
  • General administrative travel and representation expenses
What the metric indicates
  • Cost control
    A high level of such expenses may indicate inefficient management or an overly complex structure
  • Profitability
    Reducing administrative expenses while maintaining stable revenue increases operating profit
  • Comparative analysis
    Investors can compare this metric as a percentage of revenue among companies in the same industry
  • Business flexibility
    Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses AstraZeneca PLC

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - - 15.2 B - - - 10.2 B - - - - 9.84 B 11.2 B

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
15.2 B 9.84 B 11.6 B

Quarterly General and Administrative Expenses AstraZeneca PLC

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- - - - - - 3.1 B - - - 2.64 B - - - 2.94 B - - - 2.55 B - - - 2.36 B - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
3.1 B 2.36 B 2.72 B

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer General and Administrative Expenses Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
78.3 M - 2.43 % $ 254 M germanyGermany
Aptorum Group Limited Aptorum Group Limited
APM
5.41 M $ 0.79 -1.15 % $ 4.31 M chinaChina
Acorda Therapeutics Acorda Therapeutics
ACOR
89.7 M - -24.86 % $ 820 K usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
83.2 M $ 3.49 0.58 % $ 1.04 B canadaCanada
Frequency Therapeutics Frequency Therapeutics
FREQ
28.2 M - - $ 528 M usaUSA
argenx SE argenx SE
ARGX
308 M $ 700.45 -1.19 % $ 25 B niderlandNiderland
I-Mab I-Mab
IMAB
900 M - - $ 866 M chinaChina
AgeX Therapeutics AgeX Therapeutics
AGE
9.33 M - -10.17 % $ 12.2 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
1.4 B - - $ 40.3 B usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
5.51 M $ 3.6 1.41 % $ 8.66 B australiaAustralia
Biophytis SA Biophytis SA
BPTS
7.15 M - -13.47 % $ 169 M franceFrance
Grifols, S.A. Grifols, S.A.
GRFS
1.06 B $ 7.81 -2.01 % $ 6.83 B spainSpain
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
47.9 M - - $ 1.01 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
160 M $ 225.98 -1.32 % $ 5 B danmarkDanmark
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
17 M - - $ 26.5 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
4.66 M - -1.52 % $ 24.7 M usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
71.5 M $ 4.13 -5.06 % $ 105 M schweizSchweiz
Akero Therapeutics Akero Therapeutics
AKRO
37.9 M - - $ 3.67 B usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
63.1 M - - $ 86.2 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
4.95 M - -18.52 % $ 27.3 M britainBritain
Akouos Akouos
AKUS
22.2 M - 0.23 % $ 488 M usaUSA
Advaxis Advaxis
ADXS
12.2 M - -9.65 % $ 45.9 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
12.7 M - 3.16 % $ 1.9 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
13.9 M - 10.36 % $ 9.8 M usaUSA
BioCardia BioCardia
BCDA
4.4 M $ 1.26 -0.79 % $ 26.7 M usaUSA
AlloVir AlloVir
ALVR
42.9 M - 4.14 % $ 49.1 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
37.4 M - - $ 10.1 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
25.8 M - - - russiaRussia
Anika Therapeutics Anika Therapeutics
ANIK
95.8 M $ 14.2 -0.7 % $ 208 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
11.2 M - -45.71 % $ 1.2 M canadaCanada
Acer Therapeutics Acer Therapeutics
ACER
12.7 M - 2.71 % $ 14 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
13.1 M - 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
5.92 M - 5.93 % $ 314 M canadaCanada
Athersys Athersys
ATHX
20.1 M - 3.77 % $ 22.4 M usaUSA
BioNTech SE BioNTech SE
BNTX
286 M $ 91.19 1.21 % $ 27.2 B germanyGermany
Aptinyx Aptinyx
APTX
19.8 M - -39.0 % $ 4.57 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
4.64 M - -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
46.7 M $ 1.44 -1.37 % $ 367 M britainBritain
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
46.1 M $ 6.68 -4.57 % $ 183 M israelIsrael
Acasti Pharma Acasti Pharma
ACST
7.17 M - 4.01 % $ 150 M canadaCanada
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
60.8 M - - $ 521 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
99.3 M $ 7.92 1.67 % $ 1.31 B britainBritain
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
1.53 M - - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
17.4 M $ 2.54 -5.22 % $ 16 M usaUSA
Certara Certara
CERT
85.4 M $ 6.67 1.6 % $ 1.07 B usaUSA
Athira Pharma Athira Pharma
ATHA
26.1 M - - $ 269 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
3.05 M $ 3.6 -4.0 % $ 7.83 B israelIsrael
CureVac N.V. CureVac N.V.
CVAC
100 M - - $ 867 M germanyGermany
Aravive Aravive
ARAV
13 M - -13.39 % $ 1.45 M usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
7.04 M - -2.5 % $ 5.88 M usaUSA